Olaptesed pegol is under clinical development by TME Pharma and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Olaptesed pegol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olaptesed pegol overview

Olaptesed pegol (NOX-A12) is under development for the treatment of  metastatic pancreatic cancer, solid tumors including glioblastoma multiforme, glioma, metastatic colorectal cancer, pancreatic ductal adenocarcinoma and unspecified indication. The drug candidate is administered intravenously. NOX-A12 acts by targeting stromal cell-derived factor-1 (SDF-1). The drug candidate incorporates Spiegelmers technology platform. It was also under development for the treatment of hematopoietic stem cell transplantation, lupus nephritis, diabetic nephropathy, relapsed B-cell chronic lymphocytic leukemia (CLL) refractory/relapsed multiple myeloma and non-small cell lung cancer.

TME Pharma overview

TME Pharma formerly Noxxon Pharma, a subsidiary of TME Pharma NV, is a clinical and anti-cancer drug development company. It offers pipeline products such as NOX-E36 a target multiple tumor microenvironment chemokine and NOX-A12 a combination therapy for multiple cancer. The company also develops therapeutics for the treatment of tumor defenses, immunotherapy pancreatic cancer, metastatic pancreatic and colorectal cancer; glioblastoma, multiple myeloma and chronic lymphocytic leukemia and brain cancer. Noxxon’s Spiegelmer technology platform provides discovery capacities to generate additional leads under preclinical investigation. It is involved in tumor microenvironment approach for the cancer treatment. The company has collaborations with pharmaceutical, academic investigators, and research organizations. TME Pharma is headquartered in Berlin, Germany.

For a complete picture of Olaptesed pegol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.